Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

Investors Should Know: Personalized mRNA cancer vaccines are moving beyond their first major clinical success in melanoma ...

Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.

Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current ...

Moderna (NASDAQ:MRNA) stock is in focus as cancer-vaccine optimism and a pending Nasdaq-100 addition anchor the mRNA developer's healthcare headlines today.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup ...

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are rallying again as investors position ahead of a late-October data drop that could validate the first personalized cancer therapy tested at ...

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation ...